Rossari Biotech Ltd
Rossari Biotech was started in 2003. They are among the largest manufacturers of textile specialty chemicals in India. [1]
Their 3 main product categories are [2]:
- Home, personal care, and performance chemicals
- Textile specialty chemical
- Animal health and nutrition
The company has two R&D facilities, one at Silvassa manufacturing facility and a research lab at IIT Bombay. [3]
- Market Cap ₹ 3,600 Cr.
- Current Price ₹ 650
- High / Low ₹ 885 / 568
- Stock P/E 26.3
- Book Value ₹ 226
- Dividend Yield 0.08 %
- ROCE 15.8 %
- ROE 12.2 %
- Face Value ₹ 2.00
Pros
Cons
- Company has a low return on equity of 12.6% over last 3 years.
- Dividend payout has been low at 2.24% of profits over last 3 years
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Specialty Chemicals
Part of BSE SmallCap BSE Allcap BSE Commodities
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|
| 516 | 600 | 709 | 1,483 | 1,656 | 1,831 | 2,080 | 2,222 | |
| 438 | 495 | 586 | 1,299 | 1,433 | 1,581 | 1,815 | 1,948 | |
| Operating Profit | 78 | 105 | 124 | 184 | 223 | 250 | 265 | 274 |
| OPM % | 15% | 17% | 17% | 12% | 13% | 14% | 13% | 12% |
| 1 | 4 | 9 | 13 | 6 | 8 | 5 | 7 | |
| Interest | 3 | 4 | 3 | 13 | 22 | 19 | 18 | 22 |
| Depreciation | 12 | 17 | 23 | 48 | 63 | 60 | 67 | 73 |
| Profit before tax | 63 | 88 | 107 | 136 | 144 | 178 | 185 | 186 |
| Tax % | 28% | 26% | 25% | 28% | 26% | 26% | 26% | |
| 46 | 65 | 80 | 98 | 107 | 131 | 136 | 137 | |
| EPS in Rs | 103.82 | 12.86 | 15.45 | 17.74 | 19.45 | 23.66 | 24.63 | 24.68 |
| Dividend Payout % | 0% | 4% | 3% | 3% | 3% | 2% | 2% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 28% |
| 3 Years: | 12% |
| TTM: | 15% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 16% |
| 3 Years: | 12% |
| TTM: | -2% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -4% |
| 3 Years: | -10% |
| 1 Year: | -16% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 14% |
| 3 Years: | 13% |
| Last Year: | 12% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4 | 10 | 10 | 11 | 11 | 11 | 11 | 11 |
| Reserves | 119 | 277 | 398 | 794 | 904 | 1,037 | 1,174 | 1,240 |
| 8 | 67 | 0 | 8 | 74 | 119 | 218 | 353 | |
| 118 | 118 | 152 | 442 | 375 | 401 | 482 | 484 | |
| Total Liabilities | 250 | 471 | 561 | 1,255 | 1,364 | 1,567 | 1,886 | 2,088 |
| 74 | 94 | 181 | 607 | 585 | 578 | 598 | 630 | |
| CWIP | 3 | 22 | 0 | 1 | 16 | 47 | 140 | 247 |
| Investments | 0 | 18 | 0 | 36 | 51 | 63 | 84 | 20 |
| 173 | 338 | 379 | 611 | 712 | 880 | 1,063 | 1,190 | |
| Total Assets | 250 | 471 | 561 | 1,255 | 1,364 | 1,567 | 1,886 | 2,088 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| 71 | 57 | 48 | 29 | 152 | 43 | 137 | |
| -37 | -190 | -37 | -299 | -181 | -103 | -183 | |
| -29 | 157 | -25 | 292 | 61 | 16 | 65 | |
| Net Cash Flow | 5 | 23 | -14 | 22 | 32 | -44 | 19 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 61 | 57 | 74 | 75 | 78 | 85 | 83 |
| Inventory Days | 59 | 57 | 75 | 63 | 59 | 80 | 90 |
| Days Payable | 114 | 95 | 104 | 61 | 56 | 62 | 73 |
| Cash Conversion Cycle | 6 | 19 | 46 | 76 | 80 | 103 | 101 |
| Working Capital Days | 23 | 22 | 60 | 62 | 49 | 70 | 69 |
| ROCE % | 38% | 29% | 24% | 18% | 18% | 16% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
17 Oct - Audio recording of Q2 FY26 earnings call (Oct 17, 2025) posted on company website.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
17 Oct - Newspaper Publication of extract of Consolidated Unaudited Financial Results for the quarter and half year ended September 30, 2025.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
16 Oct - Q2 FY26: Revenue Rs586.1cr (+18%); EBITDA Rs71.9cr; PAT Rs36.9cr; new capacities commissioned; up to USD~8m Saudi investment.
-
Announcement under Regulation 30 (LODR)-Investor Presentation
16 Oct - Of Q2 & H1 FY26 -Earnings Presentation.
-
Intimation Of Grant Of Options Under Rossari Employee Stock Option Plan - 2019.
15 Oct - Board approved Q2/H1 results, granted 35,000 ESOPs, allotted 14,400 shares, approved up to USD ~8m investment.
Annual reports
Concalls
-
Oct 2025TranscriptNotesPPT
-
Jul 2025Transcript PPT
-
May 2025Transcript PPT REC
-
Jan 2025Transcript PPT REC
-
Oct 2024Transcript PPT
-
Oct 2024TranscriptNotesPPT
-
Jul 2024Transcript PPT
-
May 2024Transcript PPT
-
Jan 2024Transcript PPT
-
Oct 2023Transcript PPT
-
Aug 2023Transcript PPT
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Feb 2023TranscriptNotesPPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
May 2022TranscriptNotesPPT
-
Feb 2022TranscriptNotesPPT
-
Oct 2021TranscriptNotesPPT
-
Aug 2021Transcript PPT
-
Jul 2021TranscriptPPT
-
Jun 2021TranscriptPPT
-
May 2021Transcript PPT
-
Feb 2021Transcript PPT
-
Oct 2020Transcript PPT
-
Aug 2020Transcript PPT
Product Segments
The company is one of India’s leading specialty chemicals manufacturer offering 4,280+ products across 3 verticals: [1]